Incomplete retinal vascularization after ranibizumab treatment of retinopathy of prematurity

Shelley Day, Annis M. Rainey, Clio A. Harper

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

A former 24-week-old premature infant was treated with intravitreal ranibizumab (Lucentis; Genentech, South San Francisco, CA) in one eye and conventional laser in the other eye for aggressive posterior retinopathy of prematurity in both eyes. Fluorescein angiography performed at 149 weeks of age showed persistent avascularity of the temporal peripheral retina in the ranibizumabtreated eye. This case report confirms the need for long-term follow-up of patients treated with ranibizumab monotherapy.

Original languageEnglish (US)
Pages (from-to)75-78
Number of pages4
JournalOphthalmic Surgery Lasers and Imaging Retina
Volume48
Issue number1
DOIs
StatePublished - Jan 2017
Externally publishedYes

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology

Fingerprint Dive into the research topics of 'Incomplete retinal vascularization after ranibizumab treatment of retinopathy of prematurity'. Together they form a unique fingerprint.

Cite this